Summary
Objective
Method
Results
Conclusions
Key words
Introduction
- Altman R.
- Asch E.
- Bloch D.
- Bole G.
- Borenstein D.
- Brandt K.
- et al.
- Jordan K.M.
- Arden N.K.
- Doherty M.
- Bannwarth B.
- Bijlsma J.W.
- Dieppe P.
- et al.
- Zhang W.
- Doherty M.
- Arden N.
- Bannwarth B.
- Bijlsma J.
- Gunther K.P.
- et al.
Materials and methods
Retrieval of published studies
Inclusion and exclusion criteria
Quality assessment
Data extraction and outcome measures
Statistical analysis
- Jordan K.M.
- Arden N.K.
- Doherty M.
- Bannwarth B.
- Bijlsma J.W.
- Dieppe P.
- et al.
- Zhang W.
- Doherty M.
- Arden N.
- Bannwarth B.
- Bijlsma J.
- Gunther K.P.
- et al.
- Zhang W.
- Doherty M.
- Leeb B.F.
- Alekseeva L.
- Arden N.K.
- Bijlsma J.W.
- et al.
- Kristensen L.E.
- Christensen R.
- Bliddal H.
- Geborek P.
- Danneskiold-Samsoe B.
- Saxne T.
Results
Characteristics of trials

Study | Year | QS | Intervention | Design | Duration (months) | ITT | Women (%) | Joint affected | Age (years) | BMI (kg/m2) | Definite sample size | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
NE | NC | |||||||||||
Warholm | 2003 | 4 | Hyben-Vital®, 2×5×0.5 g/day=5 g/day | PG | 4 | 100 | 65 (65.0%) | K: 56, H: 44 (56% KOA) | 65.2±11.1 | n.a. | 48 | 48 |
Rein | 2004 | 4 | Hyben-Vital®, 2×5×0.5 g/day=5 g/day | CO | 3 | 112 | 71 (63.4%) | K: 59, H: 46, N: 18, S: 14, Ha: 40 (53% KOA) | 67.0±11.7 | 27.3±5.0 | 50 | 47 |
Winther | 2005 | 5 | LitoZin®, 2×5×0.5 g/day=5 g/day | CO | 3 | 94 | 54 (57.4%) | K: 58, H: 21, K&H: 15 (78% KOA) | 65.6±n.a. [range: 38–92] | 27.0±n.a. [range: 19–41] | 47 | 47 |
Overall | Median: 4, Mean: 4.3, SD: 0.5 | 5 g Rosehip powder/day | 32.7% PG | Median: 3, Mean: 3.3, SD: 0.5 | 306 | 190 (62.1%) | K: 188 (61.4% KOA) | Median: 65.6 | n.a. | 145 | 142 |
Pain reduction

Use of rescue medication
Number of responders to therapy
Adverse events and safety considerations
Discussion
- Jordan K.M.
- Arden N.K.
- Doherty M.
- Bannwarth B.
- Bijlsma J.W.
- Dieppe P.
- et al.
- Zhang W.
- Doherty M.
- Arden N.
- Bannwarth B.
- Bijlsma J.
- Gunther K.P.
- et al.
- Zhang W.
- Doherty M.
- Leeb B.F.
- Alekseeva L.
- Arden N.K.
- Bijlsma J.W.
- et al.
Conflicts of interest
Acknowledgements
References
- Pathogenesis and management of pain in osteoarthritis.Lancet. 2005; 365: 965-973
- Criteria for classification of clinical osteoarthritis.J Rheumatol Suppl. 1991; 27: 10-12
- Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association.Arthritis Rheum. 1986; 29: 1039-1049
- Inflammation in osteoarthritis.J Rheumatol Suppl. 2004; 70: 70-76
- Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease.Arthritis Rheum. 1997; 40: 723-727
- EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT).Ann Rheum Dis. 2003; 62: 1145-1155
- EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).Ann Rheum Dis. 2005; 64: 669-681
- Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis.Osteoarthritis Cartilage. 2004; 12: 263-268
- Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III.J Rheumatol. 1997; 24: 799-802
- Evidence-Based Rheumatology.1st edn. BMJ Books, London2004
- Monitoring osteoarthritis progression and therapy.Osteoarthritis Cartilage. 2004; 12: S55-S60
- The evidence for clinical efficacy of rose hip and seed: a systematic review.Phytother Res. 2006; 20: 1-3
- Osteoarthritis and nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidence.Arthritis Res Ther. 2006; 8: R127
- The anti-inflammatory properties of rose-hip.Inflammopharmacology. 1999; 7: 63-68
- Rose hip inhibits chemotaxis and chemiluminescence of human peripheral blood neutrophils in vitro and reduces certain inflammatory parameters in vivo.Inflammopharmacology. 1999; 7: 377-386
- An antiinflammatory galactolipid from rose hip (Rosa canina) that inhibits chemotaxis of human peripheral blood neutrophils in vitro.J Nat Prod. 2003; 66: 994-995
- In vivo anti-inflammatory and antinociceptive activity of the crude extract and fractions from Rosa canina L. fruits.J Ethnopharmacol. 2007; 112: 394-400
- COX-1 and -2 activity of rose hip.Phytother Res. 2007 Dec; 21: 1251-1252
- A powder made from seeds and shells of a rose-hip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial.Scand J Rheumatol. 2005; 34: 302-308
- Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses.Lancet. 1999; 354: 1896-1900
- Assessing the quality of reports of randomized clinical trials: is blinding necessary?.Control Clin Trials. 1996; 17: 1-12
- Measurement of pain.J Rheumatol. 1982; 9: 768-769
- Rose-hip in osteoarthritis (OA): a meta-analysis.Ann Rheum Dis. 2007; 66 (Abstract): 495
- Meta-analyses involving cross-over trials: methodological issues.Int J Epidemiol. 2002; 31: 140-149
- Meta-analysis combining parallel and cross-over clinical trials. III: the issue of carry-over.Stat Med. 2002; 21: 2161-2173
- Deeks J.J. Higgins J.P.T. Altman D.G. Higgins J.P.T. Green S. Analysing and Presenting Results. 4.2.5. edn. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. John Wiley & Sons, Ltd, Chichester, UK2005: 97-166 (Updated May 2005)
- Interaction revisited: the difference between two estimates.BMJ. 2003; 326: 219
- Meta-analysis: formulating, evaluating, combining, and reporting.Stat Med. 1999; 18: 321-359
- Statistical Power Analysis for the Behavioral Sciences.2nd edn. Lawrence Earlbaum Associates, 1988
- Distribution theory for Glass's estimator of effect size and related estimators.J Educational Statistics. 1981; 6: 107-128
- Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation.Med Care. 2003; 41: 582-592
- Effect sizes for interpreting changes in health status.Med Care. 1989; 27: S178-S189
- EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).Ann Rheum Dis. 2007; 66: 377-388
- Statistics notes: the odds ratio.BMJ. 2000; 320: 1468
- SAS for Mixed Models.2nd edn. SAS Institute Inc, Cary, NC2006
- Recovery of inter-block information when block sizes are unequal.Biometrika. 1971; 58: 545-554
- Integrating Results through Meta-Analytic Review Using SAS Software.1st edn. SAS Institute Inc, Cary, NC1999
- Advanced methods in meta-analysis: multivariate approach and meta-regression.Stat Med. 2002; 21: 589-624
- The combination of estimates from different experiments.Biometrics. 1954; 10: 101-129
- Quantifying heterogeneity in a meta-analysis.Stat Med. 2002; 21: 1539-1558
- Measuring inconsistency in meta-analyses.BMJ. 2003; 327: 557-560
- Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.Lancet. 2007; 370: 1706-1713
- Number needed to treat (NNT): implication in rheumatology clinical practice.Ann Rheum Dis. 2003; 62: 316-321
- The number needed to treat for adalimumab, etanercept and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review.Scand J Rheumatol. 2007; 36: 411-417
- Simpson's paradox and calculation of number needed to treat from meta-analysis.BMC Med Res Methodol. 2002; 2: 1
- Meta-analysis, Simpson's paradox, and the number needed to treat.BMC Med Res Methodol. 2002; 2: 3
- Explaining risks: turning numerical data into meaningful pictures.BMJ. 2002; 324: 827-830
- Version 1.0–1.7. Copyright© 2000–2003.Christopher Cates, 2003
- Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome.Am J Gastroenterol. 2000; 95: 1231-1238
- Value of complementary medicine exemplified by rose-hips.Gesundheitswesen. 2001; 63: 412-416
Rein E. Hansen OT, Hansen M, Assignee. Composition and method for alleviating joint pain and stiffness. United States Patent. Patent US 6,485,752 B1. 2002 Nov 26.
- The effects of a standardized herbal remedy made from a subtype of Rosa canina in patients with osteoarthritis: a double-blind, randomized, placebo-controlled clinical trial.Curr Ther Res Clin Exp. 2003; 64: 21-31
- A herbal remedy, Hyben Vital (stand. powder of a subspecies of Rosa canina fruits), reduces pain and improves general wellbeing in patients with osteoarthritis – a double-blind, placebo-controlled, randomised trial.Phytomedicine. 2004; 11: 383-391
- Complementary or alternative therapies for osteoarthritis.Nat Clin Pract Rheumatol. 2006; 2: 74-80
- Evidence of effectiveness of herbal antiinflammatory drugs in the treatment of painful osteoarthritis and chronic low back pain.Phytother Res. 2007; 21: 675-683
- SAS for Monte Carlo Studies: a Guide for Quantitative Researchers.3rd edn. SAS Institute Inc., Cary, NC, USA2001
- A survey of exact inference for contingency tables.Stat Sci. 1992; 7: 131-177
- Algorithm AS 36: exact confidence limits for the odds ratio in a 2×2 table.Appl Stat. 1971; 20: 105-110
- Can meta-analyses be trusted?.Lancet. 1991; 338: 1127-1130
- OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence.Osteoarthritis Cartilage. 2007; 15: 981-1000
- Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement.Ann Rheum Dis. 2005; 64: 29-33
- Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state.Ann Rheum Dis. 2005; 64: 34-37
- Healthcare services for those with musculoskeletal conditions: a rheumatology service. Recommendations of the European Union of Medical Specialists Section of Rheumatology/European Board of Rheumatology 2006.Ann Rheum Dis. 2007; 66: 293-301
- A simple method for converting an odds ratio to effect size for use in meta-analysis.Stat Med. 2000; 19: 3127-3131
- Acetaminophen for osteoarthritis.Cochrane Database Syst Rev. 2006; 1 (CD004257)
- Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis.JAMA. 2000; : 1469-1475
- Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis.Arch Intern Med. 2003; 163: 1514-1522
- The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest.Arthritis Rheum. 2007; 56: 2105-2110
- Glucosamine and chondroitin for treating symptoms of osteoarthritis: evidence is widely touted but incomplete.JAMA. 2000; 283: 1483-1484
- Current status of glucosamine therapy in osteoarthritis.Arthritis Rheum. 2003; 49: 601-604
- Glucosamine for pain in osteoarthritis: why do trial results differ?.Arthritis Rheum. 2007; 56: 2267-2277
- The revised CONSORT statement for reporting randomized trials: explanation and elaboration.Ann Intern Med. 2001; 134: 663-694
- Recommendations for reporting randomized controlled trials of herbal interventions: explanation and elaboration.J Clin Epidemiol. 2006; 59: 1134-1149
- Use of alternative therapies by older adults with osteoarthritis.Arthritis Rheum. 2001; 45: 222-227
- Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials.BMJ. 2004; 329: 1317
- A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis.Arthritis Rheum. 2004; 51: 746-754
- Glucosamine therapy for treating osteoarthritis.Cochrane Database Syst Rev. 2005; 2 (CD002946)
- Meta-analysis: chondroitin for osteoarthritis of the knee or hip.Ann Intern Med. 2007; 146: 580-590
Christensen R, Bartels EM, Astrup A, Bliddal H. Symptomatic efficacy of avocado/soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2007 Nov 23 [Epub ahead of print].
- Antioxidant to treat osteoarthritis: dream or reality?.Curr Drug Targets. 2007; 8: 347-357
- Reduced pain from osteoarthritis in hip joint or knee joint during treatment with calcium ascorbate. A randomized, placebo-controlled cross-over trial in general practice.Ugeskr Laeger. 2003; 165: 2563-2566
- Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis.JAMA. 2007; 297: 842-857
- The role of meta-analysis in the regulatory process for foods, drugs, and devices.JAMA. 1999; 281: 830-834
- Direct and indirect costs attributable to osteoarthritis in active subjects.J Rheumatol. 2006; 33: 1152-1158
- Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons.BMJ. 1995; 311: 1145-1148
- Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee.J Rheumatol. 1988; 15: 1833-1840
- Knee injury and Osteoarthritis Outcome Score (KOOS) – validation and comparison to the WOMAC in total knee replacement.Health Qual Life Outcomes. 2003; 1: 17
- Indexes of severity for osteoarthritis of the hip and knee. Validation – value in comparison with other assessment tests.Scand J Rheumatol Suppl. 1987; 65: 85-89
- OMERACT–OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited.Osteoarthritis Cartilage. 2004; 12: 389-399
- The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials.JAMA. 2001; 285: 1987-1991
Article info
Publication history
Identification
Copyright
User license
Elsevier user license |
Permitted
For non-commercial purposes:
- Read, print & download
- Text & data mine
- Translate the article
Not Permitted
- Reuse portions or extracts from the article in other works
- Redistribute or republish the final article
- Sell or re-use for commercial purposes
Elsevier's open access license policy